Rybrevant Faspro Receives U.S. FDA Breakthrough Therapy Designation for Patients With Advanced Head and Neck Cancer
February 19, 2026
February 19, 2026
RARITAN, New Jersey, Feb. 19 -- Johnson and Johnson Innovative Medicine issued the following news release on Feb. 18, 2026:
* * *
RYBREVANT FASPRO(TM) (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO(TM) beyond lung ca . . .
* * *
RYBREVANT FASPRO(TM) (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO(TM) beyond lung ca . . .